

Supplementary Table 1. Chemotherapy response score according to *Böhm et al. JCO 2015*.

CRS 1	No or minimal tumor response. Mainly viable tumor with no or minimal regression-associated fibroinflammatory changes, limited to a few foci. Cases in which it is difficult to decide between regression and tumor-associated desmoplasia or inflammatory cell infiltration.
CRS 2	Appreciable tumor response amid viable tumor that is readily identifiable. Tumor is regularly distributed, ranging from multifocal or diffuse regression-associated fibroinflammatory changes with viable tumor in sheets, streaks, or nodules to extensive regression-associated fibro-inflammatory changes with multifocal residual tumor, which is easily identifiable.
CRS 3	Complete or near-complete response with no residual tumor OR minimal irregularly scattered tumor foci seen as individual cells, cell groups, or nodules up to 2 mm maximum size. Mainly regression-associated fibro-inflammatory changes or, in rare cases, no or very little residual tumor in complete absence of any inflammatory response. It is advisable to record whether there is no residual tumor or whether there is microscopic residual tumor present.

NOTE. Regression-associated fibroinflammatory changes consist of fibrosis associated with macrophages, including foam cells, mixed inflammatory cells, and psammoma bodies, as opposed to tumor-related inflammation or desmoplasia.

Supplementary Table 2. Univariable DFS and OS analysis for overall population (n=365)

	Disease-free survival			Overall survival		
	HR	95% CI	p-value	HR	95% CI	p-value
Age (years)						
≤ 60	1.00	Ref.	0.784	1.00		0.386
>60	0.97	[0.77-1.21]		1.13	[0.86-1.48]	
Cycles of NACT						
3-4	1.00	Ref.	0.653	1.00	Ref.	0.562
6	0.95	[0.76-1.19]		1.08	[0.82-1.43]	
FIGO stage						
IIIC	1.00	Ref.	0.415	1.00	Ref.	0.826
IV	1.12	[0.86-1.45]		0.96	[0.69-1.34]	
Histological type						
Serous	1.00	Ref.	0.697	1.00	Ref.	
Other	0.91	[0.57-1.47]		0.91	[0.51-1.63]	0.750
PCI						
≤ 10	1.00	Ref.	< 0.001	1.00	Ref.	0.012
> 10	1.55	[1.24-1.94]		1.42	[1.08-1.86]	
Aletti score						
< 8	1.00	Ref.	< 0.001	1.00	Ref.	0.005
≥ 8	1.50	[1.20-1.88]		1.48	[1.12-1.94]	
CC-score						
CC-0	1.00	Ref.	0.033	1.00	Ref.	0.145
CC-1	1.41	[1.03-1.95]		1.32	[0.91-1.93]	
CRS						
CRS 1-2	1.00	Ref.	< 0.001	1.00	Ref.	< 0.001
CRS 3	0.47	[0.36-0.63]		0.39	[0.26-0.57]	

HR: hazard ratio

95% CI: 95% confidence interval

NACT: neoadjuvant chemotherapy

FIGO: International Federation of Gynecology and Obstetrics

PCI: peritoneal cancer index

CC-score: completeness cytoreduction score

CRS: chemotherapy response score

Supplementary Table 3. Disease-free survival and overall survival according to number of cycles and histological response to NACT.

	CRS 1-2	CRS 3	p-value
Disease-free survival (<i>median, months, 95%CI</i>)			
• 3-4 NACT	16.5 (13.9-18.4)	26.5 (20.6-43.1)	<0.001
• 6 NACT	15.9 (14.0-18.8)	29.9 (17.0-48.3)	<0.001
Overall survival (<i>median, months, 95%CI</i>)			
• 3-4 NACT	47.7 (40.0-53.7)	NR (58.5-NR)	0.001
• 6 NACT	42.9 (33.5-47.5)	104.9 (56.7-NR)	<0.001

NACT: neoadjuvant chemotherapy

Supplementary Table 4. Platinum resistance, DFS and OS according to timing of surgery in a. CRS 1-2; b. CRS3.

a. CRS 1-2

	3-4 cycles N = 174	6 cycles N = 103	p-value
Relapse < 6 months, n (%) <i>Missing</i>	45 (26.8) 6 (-)	25 (26.0) 7 (-)	0.895
Disease free survival (<i>median, 95%CI months</i>)	16.5 (13.9-18.4)	15.9 (14.0-18.8)	0.929
Overall survival (<i>median, 95%CI months</i>)	47.7 (40.0-53.7)	42.9 (33.5-47.5)	0.212

b. CRS 3

	3-4 cycles N = 45	6 cycles N = 43	p-value
Relapse < 6 months, n (%) <i>Missing</i>	3 (6.7) 0 (-)	6 (14.3) 1 (-)	0.304
Disease-free survival (median, 95%IC, months)	26.5 (20.6-43.1)	29.9 (17.0-48.3)	0.890
Overall survival (median, months)	NR	NR	0.790

NR: not reached

Supplementary Figure 1. Flow chart of the eligible and the included patients.

